Online Program

326616
Assessing US health expenditure and its increases, 1996-2012


Tuesday, November 3, 2015

Joseph Dieleman, PhD, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle,, WA
Anthony Bui, BA, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Ranju Baral, PhD, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Maxwell Birger, BS, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Anne Bulchis, MPH, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Hannah Hamavid, BA, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Cody Horst, BS, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Elizabeth Johnson, BA, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Jonathan Joseph, BS, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Liya Lomsadze, BS, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Christopher Murray, MD, DPhil, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
In 2013 the United States spent $2.9 trillion on health care, more than any previous year. To gain insight into these expenses and what is driving this growth, we divide health expenditure into 300 disease and injury categories, the setting of care, and age and sex groups. We explore the increases in health expenditure from 1996 to 2012 by assessing changes in demography, epidemiology, utilization, and prices.

We use a diverse set of survey and administrative data to divide US health expenditure into granular demographic and epidemiologic groups. We adjust our estimates for comorbidity and estimate confidence intervals. We combine our disaggregated expenditure estimates with population and disease prevalence estimates from the Global Burden of Disease 2013 study. Finally, we conduct a multivariate Shapely decomposition to quantify the causes of increases in health expenditure.

Preliminary results indicate that the primary driver of increases in total health expenditure is changes in utilization, with patients seeking care more often per illness. Increases in spending are also driven by increasing prices. Growing and aging of the population and changing epidemiological profile also contributed to increases, but less than changes in utilization and prices.

Understanding the disease and population groups responsible for the majority of health spending and its increases can provide necessary evidence for policymakers contain the growing cost of health care in the US and reallocate resources to groups most in need.

Learning Areas:

Biostatistics, economics
Provision of health care to the public
Public health or related public policy
Public health or related research

Learning Objectives:
Describe the US disease expenditure project, dividing US health expenditure into 300 disease and injury categories, the setting of care, and age and sex groups. Explain how Shapely decomposition can be used to quantify the drivers of increases in total health expenditure.

Keyword(s): Funding/Financing, Health Care Costs

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have lead the Financial Resources of Health research team at the Institute for Health Metrics and Evaluation for two years, have worked in global health and health economics for five years, and have PhD in economics. I am co-investigator or co-principal investigator on several funded grants related to tracking resources for health.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.